Under normal physiology, BCAA homeostasis is tightly regulated by controlled uptake and enzymatic catabolism. Leucine, isoleucine, and valine are essential amino acids obtained from the diet or protein turnover. They enter cells via amino acid transporters such as the L-type amino acid transporter 1 (LAT1, encoded by SLC7A5), which in most normal tissues is low but allows high-capacity BCAA import when expressed [13]. Once inside the cell, BCAAs are reversibly transaminated by branched-chain amino acid transferases (BCATs) to yield corresponding branched-chain α-ketoacids (BCKAs) [14]. BCATs use α-ketoglutarate as the amino acceptor, producing glutamate in the process. Humans have two BCAT isoforms with distinct localization: cytosolic BCAT1 and mitochondrial BCAT2 [15]. BCAT1 is normally enriched in neural and germinal tissues but is ectopically expressed in various cancers [5], whereas BCAT2 is broadly expressed in adult tissues and resides in the mitochondria of many cell types [16].

Following transamination, the BCKAs (α-ketoisocaproate from leucine, α-keto-β-methylvalerate from isoleucine, and α-ketoisovalerate from valine) are irreversibly oxidized in the mitochondrial matrix by the multi-enzyme branched-chain α-ketoacid dehydrogenase complex (BCKDH) [17]. BCKDH catalyzes the rate-limiting step of BCAA catabolism, yielding acyl-CoA derivatives that enter central metabolic pathways. Leucine’s catabolites, acetyl-CoA and acetoacetate, can fuel the tricarboxylic acid (TCA) cycle or be diverted to lipogenesis; isoleucine’s breakdown produces acetyl-CoA and propionyl-CoA (the latter converted to succinyl-CoA); valine yields succinyl-CoA [9]. Through these conversions, BCAAs provide both carbon and nitrogen for cellular energy production and biosynthesis [18]. The activity of BCKDH is tightly regulated by a dedicated kinase (BCKDK) and a phosphatase (PPM1K, also called PP2Cm) [19]. BCKDK phosphorylates and inactivates BCKDH, suppressing BCAA breakdown, while PPM1K (which localizes to mitochondria) dephosphorylates and reactivates BCKDH. This regulatory loop allows cells to fine-tune BCAA catabolic flux according to nutrient availability and demand.

In normal cells, these processes maintain BCAA levels within a narrow range and prevent toxic accumulation or depletion. For example, when BCAAs are abundant, BCKDK activity increases to curb excessive catabolism, whereas during starvation, PPM1K helps maximize BCAA oxidation for energy. In contrast, cancer cells often subvert these regulatory mechanisms [20]. Fig. 1 provides an overview of the BCAA catabolic pathway in normal cells and highlights the key points of oncogenic reprogramming (e.g., upregulation of LAT1, BCAT1, and BCKDK, and downregulation of PPM1K).

Cancer cells hijack BCAA metabolism to satisfy their heightened anabolic needs. One common strategy is to increase BCAA uptake. Many tumors overexpress LAT1 at the cell membrane, facilitating high rates of leucine import [21,22]. Elevated LAT1 at the plasma membrane sustains intracellular leucine pools that directly engage the Rag–mTORC1 axis on lysosomal membranes, thereby promoting cap-dependent translation and cell-cycle progression [23]. In parallel, tumors frequently alter the expression of BCAT and BCKDH enzymes. At the subcellular level, BCAT1 (cytosol, upregulated in many cancers) accelerates cytosolic transamination to generate glutamate and BCKAs, while BCAT2 (mitochondria) supports coupling of transamination to mitochondrial oxidation. Notably, BCAT1—normally low in adult somatic tissues—is aberrantly overexpressed in many tumors, including breast, lung, prostate, and glioma [24]. High BCAT1 levels are associated with tumor proliferation and invasion, partly through activation of PI3K/Akt/mTOR and Wnt/β-catenin signaling cascades [25]. By increasing BCAT1, cancer cells rapidly transaminate imported BCAAs, impacting multiple downstream processes. The transamination yields glutamate (which feeds into glutathione synthesis for redox balance) and generates BCKAs that can be further oxidized for energy. BCAT1-driven catabolism has been linked to enhanced growth: for instance, chronic lymphocytic leukemia cells are “avid consumers” of BCAAs, using BCAT1 bidirectionally to both degrade BCAAs and regenerate them as needed [26]. Similarly, in glioblastoma, BCAT1 upregulation (via the histone methyltransferase DOT1L) increased BCAA catabolism and supplied glutamate for antioxidant defenses, promoting tumor cell proliferation under stress [27].

On the other hand, some cancers favor accumulating BCAAs rather than fully breaking them down. This is often achieved by suppressing BCKDH activity through upregulation of BCKDK or downregulation of PPM1K. By inhibiting the irreversible oxidation of BCKAs, tumor cells accumulate BCAAs and their ketoacid derivatives in the cellular pool. The surplus leucine can continuously engage mTORC1 signaling, supporting protein synthesis and growth [28]. Moreover, abundant BCAAs provide readily available building blocks for protein and nucleotide synthesis during rapid proliferation. Indeed, studies have found that high BCKDK and low PPM1K (indicating suppressed BCAA catabolism) are associated with more aggressive cancers and poorer patient survival [29]. In breast cancer, for example, invasive tumors showed significantly elevated BCKDK and reduced PPM1K compared to normal tissue, correlating with higher relapse rates [28]. This implies that restraining BCAA breakdown is advantageous for certain tumors, likely by preserving critical nutrients and signaling molecules.

BCAA metabolic reprogramming is heterogeneous across cancer types. Some tumors (e.g., pancreatic cancers or certain leukemias) exhibit increased BCAA catabolism to derive energy and macromolecular precursors, whereas others (e.g., subsets of breast cancers) show decreased BCAA catabolism leading to BCAA accumulation [29,30]. These differences reflect the metabolic demands and microenvironmental constraints each tumor faces. Nevertheless, a unifying theme is that BCAAs are indispensable for cancer cell survival and growth—whether as fuel, as signaling cues, or as substrates for biosynthesis [31]. Tumors dynamically adjust BCAA uptake and enzyme activity to maintain this balance. Altered BCAA metabolism, in turn, influences numerous oncogenic processes: it modulates signal transduction (mTORC1 and beyond), affects the epigenetic landscape (via changes in α-ketoglutarate availability), and helps maintain redox homeostasis by supplying glutamate for glutathione and nicotinamide adenine dinucleotide phosphate (NADPH) generation [32]. Through these mechanisms, reprogrammed BCAA metabolism directly contributes to tumor cell proliferation, survival under stress, and adaptation to nutrient-poor or hypoxic conditions.

In summary, cancer cells rewire the BCAA metabolic network at multiple points—from transporter upregulation (importing more leucine) to enzyme modulation (tuning BCAT and BCKDH activity)—in order to optimize BCAA utilization for malignant growth (Fig. 1). The following sections will illustrate how these alterations drive tumor progression and interact with other cancer hallmarks, with specific examples from breast and lung tumors.

Fast-growing tumors have enormous demands for both energy and biosynthetic materials. BCAA catabolism can supply both. Oxidation of BCKAs in the TCA cycle provides ATP and intermediates for anabolic pathways. One striking example is pancreatic ductal adenocarcinoma (PDAC), a notoriously aggressive cancer [34]. PDAC cells upregulate BCAA uptake (via multiple solute carrier transporters) and rely on BCAA catabolic enzymes for proliferation. In one study, PDAC cells had significantly higher expression of BCAT2 and the BCKDH subunit BCKDHA than normal pancreatic cells, and knockdown of these enzymes selectively impaired PDAC cell growth [29]. Notably, suppressing BCKDHA in PDAC did not reduce TCA cycle metabolites or respiration, but it markedly inhibited fatty acid synthesis, indicating that PDAC diverts BCAA carbon into lipogenesis [35]. Thus, PDAC uses BCAAs as an alternative carbon source to power lipid biosynthesis for membrane production—a critical need for rapidly dividing cells. This unique dependence suggests that disrupting BCAA catabolism could selectively starve PDAC tumors of building blocks for growth. More generally, many cancers funnel BCAA-derived carbons into the TCA cycle or anabolic routes to sustain proliferation when more common fuels (like glucose) are scarce. Breast cancer provides an illustrative case: triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), often shows increased reliance on amino acids, including BCAAs [36]. Metabolomic and transcriptomic analyses indicate that TNBC tumors have higher expression of BCAA-catabolic genes on average than hormone receptor-positive tumors [28]. In TNBC patient cohorts, high BCKDK (the kinase that inactivates BCKDH) is correlated with significantly worse relapse-free survival, whereas high BCKDH (the phosphatase activating BCKDH) correlates with better outcomes [37]. This suggests that TNBCs, which suppress BCAA catabolism via BCKDK upregulation, tend to be more aggressive and prone to recurrence. Consistently, breast tumors often exhibit increased BCAA uptake and elevated intracellular BCAA levels compared to normal breast tissue. Metabolomic studies have found higher concentrations of BCAAs in breast cancer tissue and patient plasma relative to non-cancer controls [38]. This is accompanied by overexpression of BCAA transporters and enzymes. LAT1, the high-affinity leucine transporter, is upregulated in a substantial subset of breast cancers and has been linked to disease outcomes. For example, high LAT1 expression (particularly ER+ tumors) was associated with shorter survival and therapy resistance in one study [39].

Lung cancer, particularly non-small cell lung cancer (NSCLC), is another malignancy where BCAA metabolic reprogramming plays a significant role. NSCLC tumors are metabolically active and must adapt to fluctuating oxygen and nutrient conditions in the lung microenvironment [40]. Similar to breast cancer, lung cancers commonly upregulate BCAA uptake and leverage BCAA metabolism to support tumor progression and therapy resistance. Rapidly proliferating lung tumor cells have an elevated demand for essential amino acids, including BCAAs [41]. One of the best-characterized metabolic changes in lung cancer is the LAT1 overexpression. High LAT1 levels have been documented in both lung adenocarcinomas and squamous cell carcinomas, correlating with more advanced disease and poorer prognosis. In stage I lung squamous cell carcinoma, patients with LAT1-high tumors had a five-year survival of ~52%, vs. ~88% for those with LAT1-low tumors [42]. LAT1 is minimal in normal lung tissue, making it a cancer-selective transporter. By overexpressing LAT1, lung cancer cells ensure they can import leucine (and other large neutral amino acids like phenylalanine) to sustain growth signaling [43]. A continuous leucine supply via LAT1 activates mTORC1, promoting protein synthesis and cell survival in the nutrient-scarce tumor regions. Some lung cancers also overexpress other amino acid transporters (such as ASCT2 for glutamine), but LAT1 is particularly critical for BCAA intake and has attracted attention as a therapeutic target [44].

Beyond carbon supply, the nitrogen from BCAAs is equally important to cancer cells. Transamination of BCAAs yields glutamate, which feeds the glutamine pool and can support nucleotide synthesis and other nitrogen-requiring processes [45]. Some cancer cells effectively use BCAA-derived nitrogen for de novo synthesis of nucleotides and nonessential amino acids, reducing their dependence on extracellular glutamine [46]. In essence, high BCAA turnover gives tumors a metabolic edge, buffering them against nutrient fluctuations. A pan-cancer analysis of The Cancer Genome Atlas (TCGA) data found that BCAT2 gene amplification or overexpression is present in numerous tumor types and is often associated with worse survival [47]. This underscores that many malignancies benefit from ramping up BCAA catabolism to fuel their growth. The cytosolic transaminase BCAT1 is another key player. Normally low in breast tissue, BCAT1 is frequently elevated in breast tumors, especially more advanced or basal-like cancers [48]. High BCAT1 in breast cancer patients has been linked to poor prognosis [49]. In experimental models, BCAT1 overexpression promotes breast cancer cell proliferation and invasiveness, partly by supplying intermediates to the TCA cycle and activating mTOR signaling to enhance mitochondrial biogenesis [50]. Conversely, BCAT1 knockdown can reduce breast cancer cell growth and migration in vitro [51]. The importance of BCAT1 as a therapeutic target is highlighted by the discovery of a small-molecule BCAT1 inhibitor, eupalinolide B (EB), which induced apoptosis in TNBC cells and showed anti-tumor effects in preclinical models [36]. Targeting BCAT1 thus appears promising for TNBC and other subtypes with high BCAT1 activity. Intriguingly, BCAT1 may also contribute to a cancer stem cell phenotype in breast cancer. For example, interferon gamma (IFNγ) released by T cells has been reported to increase cancer stemness in breast cancer via nuclear factor kappa-B (NF-κB)/LAT1 pathway, and co-inhibition of LAT1 and BCAT1 reduced this effect [52]. Although complex, this finding ties BCAA metabolism to therapy resistance (since cancer stem-like cells are often drug-resistant) and to immune-tumor interactions.

As discussed earlier, leucine is a potent activator of mTORC1, a master regulator of cell growth. By accumulating intracellular leucine (through increased uptake or reduced breakdown), cancer cells maintain chronic mTORC1 signaling [53]. Constitutive mTORC1 activity drives unchecked protein synthesis and provides a growth and survival advantage. In estrogen receptor-positive (ER+) breast cancer, for instance, cells adapt to nutrient stress by overexpressing lethal giant larvae protein 2 (LLGL2), which promotes leucine import and mTORC1 activation [54]. This adaptation allows breast cancer cells to continue proliferating even when extracellular nutrients are low. While leucine-driven mTORC1 signaling boosts tumor growth, it can also contribute to therapy resistance (as discussed in Section 4). For example, high leucine levels and LAT1 upregulation have been linked to resistance to the anti-estrogen drug tamoxifen in ER+ breast cancer models [55,56]. Reducing leucine availability suppressed proliferation and restored drug sensitivity in these models. These findings link BCAA metabolic reprogramming directly to treatment outcomes. They exemplify how tumors exploit leucine-mTORC1 signaling to progress, but also suggest they could be vulnerable to nutrient limitation strategies.

BCAA metabolism can influence the epigenetic landscape of cancer cells, altering gene expression programs that drive tumor progression. A central player in this crosstalk is α-ketoglutarate (α-KG), the co-substrate for a family of DNA and histone demethylases [57]. By consuming α-KG during transamination, BCAT1 can modulate α-KG levels and thus affect the activity of α-KG–dependent dioxygenases. In acute myeloid leukemia (AML), for instance, high BCAT1 in leukemic stem cells depletes α-KG and induces a DNA hypermethylation profile akin to IDH-mutant leukemias [30]. This aberrant hypermethylation promotes stem cell self-renewal and blocks differentiation, contributing to leukemia aggressiveness. In solid tumors, a different mechanism has been observed: BCAT1-driven BCAA catabolism can increase α-KG production under certain conditions, affecting histone methylation status [58]. In osimertinib-resistant NSCLC, resistant cells upregulated BCAT1, leading to metabolic changes that increased α-KG availability and caused demethylation of histone H3K27 [11]. The loss of H3K27 methylation derepressed a host of glycolysis genes, thereby boosting glycolysis and fueling tumor progression [59]. Thus, BCAT1 acted as an epigenetic modulator, reprogramming gene expression to favor a more aggressive, drug-resistant phenotype. While the details differ—AML sees BCAT1 limiting α-KG (resulting in hypermethylation), whereas NSCLC sees BCAT1 increasing α-KG (resulting in hypomethylation)—both cases illustrate that dysregulated BCAA metabolism can lock cells into a malignant state via epigenetic mechanisms. The outcome is enhanced tumor progression, either by maintaining stemness or by activating stress-adaptive pathways like glycolysis.

Metastatic cancer cells often exhibit unique metabolic adaptations. BCAA reprogramming has been implicated in the metastatic cascade of several tumors. A common theme is that metastatic cells are metabolically plastic–engaging multiple nutrient pathways (glucose, glutamine, BCAAs, etc.) to meet the demands of invasion, survival in circulation, and colonization of distant organs [60]. For example, highly metastatic breast cancer cells display elevated activity in pathways spanning glucose, glutamine, and BCAA metabolism compared to non-metastatic cells. This multiplicity allows them to thrive in varying microenvironments. With regard to BCAAs specifically, one study found that suppressed BCAA catabolism correlates with greater metastatic propensity: in TNBC patients, high BCKDK (and low PPM1K) levels were associated with increased risk of relapse/metastasis [61]. This suggests that TNBC cells which preserve their BCAAs (rather than fully catabolizing them) may be better equipped to migrate and seed new tumors—possibly by channeling those amino acids into pro-migratory signaling or by using them to survive oxidative and detachment stresses during metastasis.

Conversely, some findings indicate that an excess of extracellular BCAAs can, somewhat paradoxically, inhibit metastasis via effects on the tumor microenvironment. Chi et al. reported that raising systemic BCAA levels in mice (either by a high-BCAA diet or genetically via PPM1K knockout) unexpectedly suppressed lung metastasis of breast cancer cells [28]. The high BCAA milieu reduced the cancer cells’ migratory and invasive capacity in vitro and was accompanied by lower N-cadherin expression in tumors (N-cadherin is a marker of the mesenchymal, invasive phenotype) [62]. While counterintuitive, this highlights the complex role of BCAAs: moderate BCAA availability promotes tumor cell growth, but forcing BCAA overload may tip the balance in favor of anti-tumor immune responses or other inhibitory effects (as explored in Section 5). Direct pro-metastatic roles of BCAA regulators have also been documented. BCKDK, which suppresses BCAA breakdown, has been identified as a pro-metastatic factor in colorectal cancer and hepatocellular carcinoma (HCC) [63]. Mechanistically, Src kinase-mediated phosphorylation and activation of BCKDK in HCC cells promoted cell migration and activated the ERK pathway, linking suppressed BCAA catabolism to pro-metastatic signaling [64]. These examples show that both increased and decreased BCAA catabolism can facilitate metastasis, depending on context—metastatic cells modulate BCAA metabolism in whichever way optimally suits their needs (whether for energy, structural components, or signaling molecules) during their dissemination and colonization.

Conventional chemotherapy and radiation therapy kill cancer cells largely by inflicting DNA damage and generating reactive oxygen species (ROS), leading to oxidative stress and apoptosis [67]. Tumors with reprogrammed BCAA metabolism can blunt this oxidative stress, thereby surviving treatment. Enhanced leucine catabolism, in particular, yields metabolites that bolster cellular antioxidant defenses. Leucine’s transamination produces α-ketoisocaproate (α-KIC), which can directly scavenge ROS and increase the cell’s antioxidant capacity [68]. Furthermore, BCAA transamination via BCAT1/2 generates glutamate, a precursor for glutathione (GSH) synthesis. The resulting rise in intracellular glutamate drives cystine import and GSH production, which quenches chemotherapy-induced ROS and helps maintain redox homeostasis [69]. For instance, upregulation of BCAT2 in cancer cells elevates glutamate and GSH levels, thereby antagonizing ferroptosis (iron-dependent, ROS-mediated cell death) and protecting the cells from oxidative damage caused by treatment [70]. Additionally, BCAT1 itself contains a conserved Cys–X–X–Cys motif that can act as a redox switch to detoxify peroxides like H₂O₂, meaning BCAT1 overexpression directly buffers intracellular ROS [71].

Apart from boosting antioxidant molecule production, leucine-dependent signaling activates survival pathways. Persistent leucine/mTORC1 signaling promotes anabolic metabolism and upregulates anti-stress programs, including the expression of antioxidant enzymes and anti-apoptotic factors [72,73]. In essence, continuous mTORC1 activity helps tumor cells counteract the growth-inhibiting and pro-apoptotic signals triggered by chemo/radiotherapy. By sustaining ATP production, protein synthesis, and stress response gene expression, mTORC1 signaling enables cancer cells to weather the treatment-induced storm. Together, these metabolic adaptations raise the threshold for therapy-induced cell death. Tumors with high BCAA flux maintain redox balance despite ROS-generating treatments, making them less sensitive to cytotoxic agents. Supporting this, inhibiting BCAA-preserving mechanisms can resensitize tumors to therapy: for example, BCKDK inhibition in TNBC forced increased BCAA oxidation, depleted GSH, and stalled protein synthesis, which made the cancer cells more vulnerable to doxorubicin [37].

Another avenue through which BCAA regulators contribute to chemoresistance is by modulating DNA repair. Recent evidence suggests that BCKDK can translocate to the nucleus and enhance the repair of DNA double-strand breaks. In breast cancer cells, nuclear BCKDK was reported to promote homologous recombination repair (HRR) by stabilizing the RAD51 recombinase (via phosphorylation of the E3 ligase RNF8). This accelerated the repair of chemotherapy-induced DNA damage, aiding cell survival. Conversely, inhibiting BCKDK disrupted RAD51 stabilization and sensitized tumors to DNA-damaging agents. Although this is a non-metabolic function of BCKDK, it underlines how deeply embedded BCAA regulatory proteins are in the cellular networks that determine therapy response [45].

In summary, branched-chain amino acid reprogramming endows cancer cells with a multifaceted defense against chemo- and radiotherapy. By elevating antioxidant defenses (GSH and other ROS scavengers), maintaining energy and biosynthesis via mTORC1, and even enhancing DNA repair, tumor cells can survive levels of damage that would kill more metabolically naive cells. This explains why cancers with high BCAA metabolic activity often exhibit chemoresistance.

BCAA metabolism can also undermine targeted therapies, such as hormone-blocking treatments and kinase inhibitors. In ER+ breast cancer, we have seen that leucine-driven mTORC1 signaling can cause resistance to endocrine therapy (tamoxifen). Tamoxifen-resistant cells often upregulate LAT1 and increase leucine uptake, maintaining mTORC1 activity to bypass the need for estrogen signaling [55,56]. Targeting this metabolic adaptation—for instance, by limiting leucine or inhibiting LAT1—can restore sensitivity to hormonal therapy in preclinical models [54]. Thus, metabolic interventions may overcome certain forms of endocrine resistance.

Another clear example is in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs) like osimertinib. Tumors eventually develop resistance to TKIs, and metabolic reprogramming plays a role. Proteomic analyses of TKI-resistant NSCLC revealed consistent upregulation of BCAT1 in resistant cells [11]. Functionally, BCAT1 proved critical for maintaining the resistant state: its inhibition re-sensitized these cells to EGFR blockade. Mechanistically, BCAT1 reprogrammed cellular metabolism and epigenetics (increasing α-KG and promoting histone demethylation of glycolytic genes, as discussed in Section 3.3), thereby enabling cells to escape EGFR dependence. When BCAT1 was inhibited (for example, by the small-molecule WQQ-345), those metabolic and epigenetic changes were reversed, and previously resistant tumors responded to EGFR TKIs again [11,74].

These cases underscore a broader principle: when oncogenic signaling is inhibited by targeted drugs, cancer cells may turn to metabolic pathways like BCAA utilization to sustain survival. By cutting off that metabolic escape route—via BCAA metabolic inhibitors or dietary manipulation—we can potentially counteract resistance. Early-stage research is exploring combinations such as EGFR inhibitors with BCAT1 inhibitors in lung cancer, and anti-estrogen therapy with LAT1 inhibitors or leucine restriction in breast cancer.

Finally, BCAA metabolic reprogramming can impede the efficacy of immunotherapies by creating a nutrient-deprived, immunosuppressive tumor microenvironment. Cancer immunotherapy (like immune checkpoint blockade or CAR-T cell therapy) relies on functional, metabolically active T cells and NK cells to attack the tumor. However, tumors with high BCAA consumption effectively starve these immune cells. Tumor cells can deplete extracellular leucine, leaving infiltrating T cells without enough fuel to proliferate or activate their effector functions. Even if a checkpoint inhibitor unleashes the T cells, those T cells may fail to expand or produce cytotoxic molecules if they are leucine-starved. This metabolic form of immune evasion can manifest as primary or acquired resistance to immunotherapy.

There is evidence supporting this concept. A pan-cancer analysis found that tumors with high BCAT2 expression often had reduced T cell infiltration, consistent with a microenvironment less hospitable to T cells [47]. More directly, a recent preclinical study demonstrated that supplementing BCAAs can enhance T cell activity and improve responses to immunotherapy: in an animal model, adding BCAAs (to counteract tumor-imposed depletion) led to stronger CD8+ T cell effector function and synergized with anti-PD-1 therapy to better control tumor growth [31]. This suggests that, at least in some contexts, metabolic competition for BCAAs is a limiting factor for immunotherapy success.

On the other hand, simply feeding BCAAs to patients is a double-edged sword, as it might also nourish the tumor. Therefore, a more refined approach involves modifying immune cells to be less dependent on external BCAAs. A striking example is the engineering of CAR-T cells with a deleted BCKDK gene, which keeps their BCKDH complex active and allows them to utilize BCAAs more efficiently for energy [12]. These BCKDK-knockout CAR-T cells showed enhanced persistence and anti-tumor activity in solid tumor models, effectively overcoming the nutrient starvation imposed by the tumor. Such metabolic reprogramming of immune cells could make cell therapies much more potent in nutrient-poor tumor environments.

In summary, tumors can use BCAA metabolism as a shield not only against drugs and radiation but also against the immune system. By depleting key amino acids and activating stress resistance pathways, cancer cells make themselves less killable by both conventional therapies and immune-mediated attack. Recognizing and counteracting this phenomenon—through metabolic modulation of the tumor or the immune cells—represents a frontier in improving immunotherapy outcomes.

Solid tumors often create a nutrient-depleted TME by consuming available fuels. T cells infiltrating such tumors face scarcity of glucose, amino acids, and oxygen, which impairs their effector functions [78]. Rapidly proliferating tumor cells can deplete local leucine and other BCAAs, starving nearby T cells. Activated T cells, especially CD8+ cytotoxic T lymphocytes, have a high demand for leucine—they need leucine uptake to fuel clonal expansion and to activate mTORC1, which drives production of interferon-γ, granzymes, and other effector molecules [79,80]. If cancer cells with high LAT1 expression sequester most of the leucine, T cells in the vicinity become deprived of this essential nutrient. Consequently, their proliferation or cytokine production leads to a blunted immune attack on the tumor [81]. This scenario is analogous to tumors outcompeting T cells for glucose (the Warburg effect) or degrading tryptophan via IDO to impair T cell function. BCAA depletion in the TME thus diminishes T cell metabolic fitness and effector capacity, contributing to immune evasion by the tumor.

Leucine itself is also a critical signal for T cells. Upon activation, naive T cells dramatically upregulate amino acid transporters (including LAT1) to import leucine and other amino acids, which is required for turning on mTORC1 and shifting the T cells into a growth and effector mode [82]. In the absence of sufficient leucine, T cells fail to properly activate. For instance, genetic deletion of LAT1 in T cells leads to defective blast formation and severely reduced CD8+ T cell responses, due to the inability to uptake leucine and activate mTOR [83]. Different T cell subsets have distinct metabolic profiles: effector T cells rely heavily on anabolic metabolism and mTORC1 signaling, whereas regulatory T cells (Tregs) and memory T cells favor more oxidative metabolism and are somewhat less dependent on high exogenous leucine [84]. Nevertheless, BCAA metabolism appears important even for Tregs—BCAT1 is induced during human T cell activation and may influence the balance between effector and regulatory phenotypes [79]. In summary, leucine availability and mTORC1 signaling act as checkpoints for T cell activation and function. Tumors that induce leucine scarcity effectively push T cells into a nutrient-starved state, undermining anti-tumor immunity.

Natural killer (NK) cells, key innate immune effectors, are also influenced by BCAA levels. When activated (e.g., by cytokine IL-15), NK cells increase their metabolic activity similar to T cells—ramping up glycolysis and protein synthesis to support their cytotoxic functions [28]. In the TNBC study by Chi et al., boosting systemic BCAA levels (via diet or genetic means) significantly enhanced NK cell infiltration into tumors and their activity there. NK cells from high-BCAA conditions expressed higher levels of granzyme B and IFN-γ, indicating a stronger anti-tumor response. The rationale is that normally, tumor cells outcompete NK cells for nutrients in the TME. but in a BCAA-rich environment, NK cells can obtain sufficient leucine to sustain mTORC1 signaling and their effector program. Indeed, in Ppm1k-knockout mice (which have elevated circulating BCAAs due to defective BCAA catabolism), NK cells are better equipped to control tumor growth, evidenced by increased tumor cell apoptosis and slower tumor progression [28,85]. This suggests that metabolic interventions (like BCAA supplementation) might boost innate immune surveillance in some contexts. However, caution is warranted: excess leucine could simultaneously fuel tumor growth if cancer cells can efficiently utilize it. Therefore, any such strategy would need to be carefully timed or targeted, potentially providing short-term bursts of BCAAs to support immune cells during critical periods of an immune response.

Compared to lymphocytes, less is known about how BCAA availability impacts myeloid cells in the TME, such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). Macrophages can adapt their metabolism depending on their polarization: classically activated M1 macrophages (pro-inflammatory) rely mainly on glycolysis, whereas alternatively activated M2 macrophages (immunosuppressive) rely more on oxidative metabolism and mitochondrial respiration [86]. A tumor’s metabolic profile could influence this balance. For example, arginine depletion by tumor cells (via arginase) is known to push macrophages toward an immunosuppressive phenotype. By analogy, a low-BCAA environment might limit macrophage protein synthesis and cytokine production, impairing M1 polarization and tilting macrophages toward an M2-like, tumor-promoting state [87]. Conversely, an abundance of BCAAs might “re-energize” macrophages and dendritic cells, potentially enhancing antigen presentation and T cell stimulation. Direct evidence for BCAA effects on TAMs is sparse, but one can speculate that tumors with high BCAA catabolic activity create conditions that favor immunosuppressive myeloid cells. In support of this, a multi-omics study found that high BCAT2 expression in tumors correlated with reduced T cell infiltration and potentially higher levels of suppressive cells in some cancers [47,88]. While correlative, this finding is consistent with the idea that aggressive BCAA metabolism by tumors can help construct an immune microenvironment that is less hostile to the cancer. As for MDSCs, these cells thrive in and help maintain immunosuppressive environments. They are known to alter amino acid metabolism (for instance, MDSCs consume arginine and cystine and produce immunosuppressive metabolites). It is plausible that MDSCs are also influenced by BCAA levels or even contribute to BCAA depletion in the TME, although this hasn’t been explicitly shown yet. Future studies are needed to delineate how BCAAs affect the recruitment or function of MDSCs and TAMs.

In summary, tumor-driven BCAA metabolic changes reverberate through the immune system: starving T and NK cells of nutrients and potentially skewing macrophages toward tumor-friendly phenotypes. This creates a vicious cycle where an actively metabolizing tumor dampens immune attack, allowing it to grow unchecked.

Because LAT1 is the principal gateway for leucine entry into many tumors, it has been a prime target for therapy. Blocking LAT1 essentially “cuts off the supply line” of leucine and other essential amino acids. The most advanced LAT1 inhibitor is JPH203 (also known as KYT-0353), a selective small-molecule inhibitor of LAT1 [95]. In preclinical studies, JPH203 potently suppressed proliferation of LAT1-high cancer cell lines and reduced tumor growth in animal models by inducing nutrient starvation stress. Importantly, LAT1 is expressed at high levels in tumors but only at minimal levels in most normal adult tissues (notable exceptions include the blood-brain barrier and some hepatocytes), suggesting a favorable therapeutic window [96]. JPH203 has progressed to human trials. A first-in-human Phase I trial in patients with advanced solid tumors (mainly biliary tract and pancreatic cancers) found that JPH203 was generally well tolerated; the dose-limiting toxicity was a reversible elevation of bilirubin, likely due to on-target effects of LAT1 inhibition in liver cells (LAT1 helps transport bilirubin conjugates) [97]. Notably, some patients achieved stable disease for several months on JPH203, and one patient with biliary tract cancer had a partial tumor response. These early signs of activity have led to a Phase II trial focusing on advanced biliary tract cancers, where LAT1 is often highly expressed [98].

Beyond JPH203, other LAT1 inhibitors are under development. For example, SKN103 is a novel LAT1-specific inhibitor reported to have strong anti-tumor effects in preclinical models [99]. Interestingly, several approved drugs or endogenous hormones can interact with LAT1 as transported substrates (e.g., levodopa and thyroid hormones) and therefore may show weak competitive effects in vitro, but they are not potent or selective enough to serve as clinical LAT1 inhibitors [100,101]. The main challenge for LAT1 inhibitors will be ensuring that blocking leucine uptake in tumors does not cause systemic malnutrition or prompt cancer cells to compensate by upregulating other transporters or scavenging nutrients from their environment. So far, the clinical data are encouraging that a balance can be struck: with careful monitoring of patients’ nutritional status and perhaps dietary support, LAT1 inhibition can be delivered safely. If effective, LAT1 inhibitors could be combined with other therapies (e.g., mTOR inhibitors or chemotherapy) for a one-two punch—cutting off nutrient supply and directly hitting growth signaling.

BCAT1 has emerged as a key metabolic enzyme in numerous tumors, particularly those that thrive in hypoxic or nutrient-stressed niches. Inhibiting BCAT1 is an attractive strategy because it can disrupt multiple pro-tumor processes at once: it slows BCAA catabolism (potentially starving the TCA cycle), it may cause toxic buildup of BCKAs, it reduces glutamate production (impacting redox balance and nucleotide synthesis), and it can restore normal α-KG levels (thereby potentially reversing certain epigenetic changes). Several BCAT1 inhibitors have been identified:

Compared to BCAT1, the mitochondrial BCAT2 has received less attention, but it is crucial for BCAA catabolism in certain contexts (such as in PDAC, some liver cancers, and potentially in systemic BCAA metabolism related to cachexia). Researchers at GlaxoSmithKline recently developed potent and selective BCAT2 inhibitors based on a 2-aryl benzimidazole scaffold [105]. Through medicinal chemistry optimization, they achieved nanomolar-range inhibition of BCAT2. These compounds were initially tested in non-cancer settings: for example, in models of heart failure and cancer cachexia, where excessive BCAA breakdown is detrimental (heart failure patients often have hyperactive BCAA catabolism leading to cardiac dysfunction). In those models, BCAT2 inhibitors helped by raising circulating BCAA levels and reducing toxic BCKA accumulation, confirming on-target activity [106]. Translating BCAT2 inhibition to cancer means using it to push cancer cells into a metabolic corner—forcing them to either accumulate BCKAs or activate BCKDH and potentially overproduce ROS or deplete NAD+ (since BCKDH consumes NAD+). A recent preclinical study in 2023 did exactly this: they tested a BCAT2 inhibitor in a PDAC mouse model, since PDAC cells often have high BCAT2 expression. The BCAT2 inhibitor significantly slowed tumor growth and, intriguingly, induced markers of ferroptotic cell death in the tumors [69]. This aligns with separate findings that loss of BCAT2 can remove a cell’s protection against ferroptosis, making them more susceptible to iron-dependent oxidative cell death. Thus, BCAT2 inhibitors could potentially synergize with treatments that induce oxidative stress or ferroptosis in cancer cells. No BCAT2 inhibitor has reached clinical trials yet, and one reason is the safety concern: systemic BCAT2 inhibition would raise circulating BCAA levels (as seen in genetic BCAT2 or BCKDH deficiencies), which can lead to metabolic complications such as insulin resistance or neurologic issues akin to maple syrup urine disease [107]. Therefore, any cancer therapy targeting BCAT2 might require short-term dosing or targeted delivery. For example, encapsulating a BCAT2 inhibitor in a nanoparticle to concentrate its effect in the tumor could minimize systemic exposure and toxicity [108].

Inhibiting BCKDK is conceptually the flip side of what many tumors do. Tumors upregulate BCKDK to save their BCAAs; inhibiting BCKDK forces them to burn those precious amino acids. The prototype BCKDK inhibitor is a compound called BT2, which allosterically inactivates BCKDK. BT2 has actually been used in mice to treat diet-induced diabetes, as chronic BCKDK inhibition lowers BCAA levels and improves insulin sensitivity (high BCAAs are linked to insulin resistance) [92]. In cancer models, BCKDK inhibition has produced some encouraging results. As mentioned, in TNBC models, blocking BCKDK (with BT2 or by shRNA) led to slower tumor growth and enhanced the efficacy of chemotherapy [28,37]. Essentially, by preventing the tumor from hoarding BCAAs, BCKDK inhibition causes the tumor to over-oxidize BCAAs, which can create an energetic shortfall or metabolic byproducts that stress the cell. It may also deprive the tumor of leucine signaling for mTOR, compounding the anti-tumor effect [109]. Preclinical studies in HCC have also shown that turning BCKDH “back on” (via BCKDK inhibition or PPM1K activation) can suppress cancer aggressiveness. Tumors with active BCKDH cannot accumulate BCAAs and seem less able to invade or metastasize [110]. These findings make a compelling case for BCKDK as a target.

The challenge, as with BCAT2, is the shadow of maple syrup urine disease—a condition where BCKDH is overly active or BCKDK is deficient, leading to continuous BCAA breakdown and dangerously low BCAA levels in the body. Patients with MSUD suffer from neurological damage if not managed with a strict diet. A systemic BCKDK inhibitor could potentially induce an MSUD-like state if overdone [111]. However, in the context of cancer therapy, one might use a BCKDK inhibitor in short bursts (e.g., a few days at a time) or in a localized manner. Another approach is to tie the BCKDK inhibitor to a tumor-targeting moiety (like an antibody or a ligand that the tumor uptakes), thereby concentrating it in cancer cells. Additionally, since some tumors might have specific kinases that regulate BCKDK, blocking those kinases (for instance, blocking Src in an HCC where Src activates BCKDK [64]) could be a more tumor-selective way to achieve the same end. Interestingly, metabolic side effects of BCKDK inhibition might be mitigated by dietary support—if patients on a BCKDK inhibitor up their intake of BCAAs slightly (or overall protein), it might offset losses in normal tissues while still hurting the tumor. These are the kinds of nuances that will need to be ironed out in translational research [112].

Because BCAAs come from the diet, adjusting what patients eat is a straightforward-sounding, yet powerful, tool. Researchers have explored both BCAA restriction and supplementation in different scenarios.

One of the most exciting emerging areas is combining BCAA-targeted approaches with other therapies, especially immunotherapies. The rationale is clear: tackle the tumor’s metabolism while simultaneously attacking it with immune or targeted agents, hitting it from multiple sides.

Targeting cancer metabolism, including BCAA pathways, comes with unique challenges. Unlike a mutated oncogene, which might be unique to a tumor, metabolic enzymes are also present in normal tissues. Thus, on-target side effects are a concern. BCAAs are vital for normal muscle, brain, and immune function. Indeed, patients with rare inborn errors in BCAA metabolism (like MSUD) show how essential balanced BCAA levels are—those patients require meticulous dietary management for life. The hope is that cancer cells’ addiction to BCAAs is greater and more indispensable than normal cells’ usage. So far, clinical experiences like the JPH203 trial suggest that short-term inhibition of BCAA pathways can be tolerated in adults, but long-term effects need observation [120]. One way to maximize safety and efficacy is through precision medicine approaches.